The news
On October 21, 2026, Cencora, Inc. (NYSE: COR), the pharmaceutical distributor ranked #10 on the Fortune 500, announced a definitive agreement to acquire American Oncology Network, Inc. (OTCQX: AONC), a physician-led network of more than 350 oncology providers across 21 states. The transaction values AON at an enterprise value of $2.4 billion — $2.3 billion payable at closing plus contingent value rights of up to $100 million tied to specified conditions.
Cencora already owns about 4% of AON's equity and agreed to acquire everything it doesn't own. Certain AON stockholders may roll over up to 25% of their equity; if they do, Cencora expects to pay roughly $1.7 billion at closing to lift its ownership to 75%. The deal is expected to be accretive to Cencora's adjusted diluted EPS in the second year after closing.
The deal
The acquisition deepens Cencora's reach in community oncology — outpatient cancer care delivered outside hospital systems, one of healthcare's hottest dealmaking arenas. AON was founded in 2018 and pioneered a physician-led management services organization (MSO) model that keeps clinical decisions with doctors while centralizing back-office support, technology, and ancillary services. The transaction adds AON's footprint to Cencora's existing MSO platform and extends its presence into 12 additional states.
AON's board approved the agreement on the unanimous recommendation of a special committee of independent directors, and closing awaits regulatory clearances and AON shareholder approval. Cencora is advised by Citi (lead) and J.P. Morgan, with Holland & Knight and Sidley Austin on legal; AON's special committee is advised by Moelis, with McDermott Will & Schulte and Cleary Gottlieb providing counsel. Cencora also updated its fiscal 2026 guidance alongside the deal, lifting expected adjusted diluted EPS to at least $17.90, and said it would discuss fiscal 2027 expectations on its November 4 earnings call.
Background and context
Community oncology has become a consolidation magnet. Hospital systems have been absorbing independent practices for years, but distributors like Cencora are building a parallel empire: buying the practice-management infrastructure that lets doctors stay independent while accessing scale. The logic is straightforward — distributors control drug supply and pharmacy economics, so adding the practices that administer those drugs creates a vertically integrated cancer-care platform.
The precedents are large and recent. In 2024, Cardinal Health agreed to acquire Integrated Oncology Network for $1.12 billion. McKesson took a controlling interest in Core Ventures — the MSO of Florida Cancer Specialists — for $2.49 billion. And Cencora itself took majority control of OneOncology in 2025 in a roughly $5 billion deal. Evercore ISI analyst Elizabeth Anderson noted the AON deal diversifies Cencora's oncology presence by adding AON's focus on smaller providers, complementing OneOncology's larger practices.
The MSO model sits at the center of the physician-practice economy. An MSO handles billing, compliance, HR, procurement, and IT for a network of practices; the doctors retain clinical control and, in physician-friendly states, ownership. Investors love the structure because revenue is recurring and consolidation-ready. Regulators, meanwhile, have grown warier: the FTC and state attorneys general are increasingly scrutinizing private-equity rollups of medical practices, which is why the special-committee process and regulatory clearance language in this deal matter.
Why it matters for founders
Cencora's second mega-oncology deal in two years confirms the MSO rollup thesis: distributors will pay multi-billion-dollar valuations for platforms that aggregate independent physicians. If you're building practice-management software, revenue-cycle automation, or care-coordination tooling for specialty medicine, the buyers of your company are no longer just private-equity rollups — they're the Fortune 500 distributors with $300 billion in annual revenue and standing M&A budgets.
Two tactical lessons: first, AON was bought by an existing minority investor. Cencora had held its ~4% stake since 2020 — six years of partnership before acquisition. Corporate venture and strategic minority checks are often the on-ramp to an exit. Second, physician-led positioning is the moat: AON's marketing stresses that clinical decisions rest with doctors, which matters both to the practices it recruits and to the regulators reviewing the deal. Structure your healthcare startup so the physicians stay in charge and you own the infrastructure around them.
Why it matters for investors
For public investors, the deal reads as incremental rather than transformational — Barclays' Glen Santangelo called it a continuation of strategy, and Cencora shares dipped more than 1% on the news. But the valuation mechanics are instructive: $2.4 billion enterprise value with a contingent-value kicker and a 25% rollover option is a deal engineered for downside protection and alignment, not a trophy premium.
For private investors, the signal is that community oncology remains bid-worthy but selective. AON's ~350 providers across 21 states commanded roughly $6.9 million in enterprise value per provider. If you hold MSO-adjacent assets, benchmark your deal against Cardinal's $1.12B, McKesson's $2.49B, and Cencora's $5B and $2.4B buys — the buyer universe is consolidating fast, and the distributors are becoming the exit of choice over PE sponsors.
Angeled.com connects founders with investors.
Source: Cencora to buy American Oncology Network in $2.4 billion deal — Reuters
Source: Cencora To Acquire American Oncology Network In $2.4 Billion Deal — Pulse2
Read Next
Inovalon to Acquire DrFirst, Uniting Healthcare Data With Prescribing Workflows
Oura to Acquire Counsel Health for $625 Million, Putting a Doctor Behind the Ring
Anthropic Files Updated IPO Prospectus Aiming at a $1.4 Trillion Valuation
Archrock to Acquire HiVolt Energy for Up to $450 Million
Barrick Mining Files to Spin Off and List Its North American Gold Business
What a $1.4 Trillion Anthropic IPO Would Mean for Founders



